Effects of local delivery of d-amino acids from biofilm-dispersive scaffolds on infection in contaminated rat segmental defects
Source abstract
Abstract
Infectious complications of open fractures continue to be a significant factor contributing to non-osseous union and extremity amputation. The persistence of bacteria within biofilms despite meticulous debridement and antibiotic therapy is believed to be a major cause of chronic infection. Considering the difficulties in treating biofilm-associated infections, the use of biofilm dispersal agents as a therapeutic strategy for the prevention of biofilm-associated infections has gained considerable interest. In this study, we investigated whether local delivery of D-Amino Acids (D-AAs), a biofilm dispersal agent, protects scaffolds from contamination and reduces microbial burden within contaminated rat segmental defects in vivo. In vitro testing on biofilms of clinical isolates of Staphylococcus aureus demonstrated that D-Met, D-Phe, D-Pro, and D-Trp were highly effective at dispersing and preventing biofilm formation individually, and the effect was enhanced for an equimolar mixture of D-AAs. Incorporation of D-AAs into polyurethane scaffolds as a mixture (1:1:1 D-Met:D-Pro:D-Trp) significantly reduced bacterial contamination on the scaffold surface in vitro and within bone when implanted into contaminated femoral segmental defects. Our results underscore the potential of local delivery of d-AAs for reducing bacterial contamination by targeting bacteria within biofilms, which may represent a treatment strategy for improving healing outcomes associated with open fractures.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Bacterial biofilms and quorum sensing · Antimicrobial agents and applications · Antimicrobial Peptides and Activities
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (71)
Show source-provided references
1. Osteomyelitis10.1016/S0140-6736(04)16727-5 ↗
2. Antibiotics for treating chronic osteomyelitis in adults
3. Infectious complications and soft tissue injury contribute to late amputation after severe lower extremity trauma
4. Biofilm theory can guide the treatment of device-related orthopaedic infections10.1097/00003086-200508000-00003 ↗
5. Bacterial biofilms: a common cause of persistent infections10.1126/science.284.5418.1318 ↗
6. Osteomyelitis and the role of biofilms in chronic infection10.1111/j.1574-695X.2007.00357.x ↗
7. Mode of growth of bacterial pathogens in chronic polymicrobial human osteomyelitis10.1128/jcm.22.6.924-933.1985 ↗
8. Adherent bacterial colonization in the pathogenesis of osteomyelitis10.1126/science.4001933 ↗
9. Introduction to biofilm10.1016/S0924-8579(99)00018-7 ↗
10. The challenge of treating biofilm-associated bacterial infections10.1038/sj.clpt.6100247 ↗
11. Bacterial biofilms: from the natural environment to infectious diseases10.1038/nrmicro821 ↗
12. Biofilm development by clinical isolates of Staphylococcus spp. from retrieved orthopedic prostheses10.3109/17453674.2010.537810 ↗
13. Association between methicillin susceptibility and biofilm regulation in Staphylococcus aureus isolates from device-related infections10.1128/JCM.02280-06 ↗
14. Biofilm formation by clinical isolates and the implications in chronic infections10.1186/1471-2334-13-47 ↗
15. Molecular techniques to detect biofilm bacteria in long bone nonunion: a case report10.1007/s11999-011-1843-9 ↗
16. Should we stay or should we go: mechanisms and ecological consequences for biofilm dispersal10.1038/nrmicro2695 ↗
17. Biofilm formation and dispersal and the transmission of human pathogens10.1016/j.tim.2004.11.004 ↗
18. Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses10.1177/0022034509359403 ↗
19. New antibiotic agents and approaches to treat biofilm-associated infections10.1517/13543776.2010.505923 ↗
20. In vitro efficacy of bismuth thiols against biofilms formed by bacteria isolated from human chronic wounds10.1111/j.1365-2672.2011.05110.x ↗
21. Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in staphylococci10.1038/ja.2011.113 ↗
22. Biofilm dispersal in Xanthomonas campestris is controlled by cell-cell signaling and is required for full virulence to plants10.1073/pnas.1833360100 ↗
23. Cis-2-decenoic acid inhibits S. aureus growth and biofilm in vitro: a pilot study10.1007/s11999-012-2388-2 ↗
24. RNAIII-inhibiting peptide enhances healing of wounds infected with methicillin-resistant Staphylococcus aureus10.1128/AAC.01340-07 ↗
25. Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo10.1128/AAC.00045-11 ↗
26. D-amino acids trigger biofilm disassembly10.1126/science.1188628 ↗
27. Inhibitory effects of D-amino acids on Staphylococcus aureus biofilm development10.1128/JB.05534-11 ↗
28. In vitro study of the metabolic effects of D-amino acids10.1002/(SICI)1520-636X(1996)8:1<24::AID-CHIR6>3.0.CO;2-G ↗
29. Characterization of a rabbit model of staphylococcal osteomyelitis10.1002/jor.1100150314 ↗
30. Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo10.1128/AAC.00484-09 ↗
31. Investigation of biofilm formation in clinical isolates of Staphylococcus aureus10.1007/978-1-59745-468-1_10 ↗
32. Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices10.1128/jcm.22.6.996-1006.1985 ↗
33. Synthesis and in vitro biocompatibility of injectable polyurethane foam scaffolds10.1089/ten.2006.12.1247 ↗
34. Rapidly degraded terpolymers of dl-lactide, glycolide, and epsilon-caprolactone with increased hydrophilicity by copolymerization with polyethers10.1002/jbm.820241011 ↗
35. Synthesis, in vitro degradation, and mechanical properties of two-component poly(ester urethane)urea scaffolds: effects of water and polyol composition10.1089/ten.2006.0395 ↗
36. Injectable biodegradable polyurethane scaffolds with release of platelet-derived growth factor for tissue repair and regeneration10.1007/s11095-008-9618-z ↗
37. Determination of amino acid without derivatization by using HPLC-HILIC column
38. Influence of surface porosity and pH on bacterial adherence to hydroxyapatite and biphasic calcium phosphate bioceramics10.1099/jmm.0.002758-0 ↗
39. Sustained release of vancomycin from polyurethane scaffolds inhibits infection of bone wounds in a rat femoral segmental defect model10.1016/j.jconrel.2010.04.002 ↗
40. Dual-purpose bone grafts improve healing and reduce infection10.1097/BOT.0b013e31821f624c ↗
41. Early antibiotics and debridement independently reduce infection in an open fracture model
42. Guidelines for the prevention of infections associated with combat-related injuries: 2011 update: endorsed by the Infectious Diseases Society of America and the Surgical Infection Society
43. On the use of the Weibull function for the discernment of drug release mechanisms10.1016/j.ijpharm.2005.10.044 ↗
44. The effects of rhBMP-2 released from biodegradable polyurethane/microsphere composite scaffolds on new bone formation in rat femora10.1016/j.biomaterials.2009.08.038 ↗
45. Effectiveness of local antibiotic delivery with an osteoinductive and osteoconductive bone-graft substitute10.2106/JBJS.C.01670 ↗
46. The use of an antibioticimpregnated, osteoconductive, bioabsorbable bone substitute in the treatment of infected long bone defects: early results of a prospective trial10.1097/00005131-200210000-00002 ↗
47. Silica sol-gel for the controlled release of antibiotics. I. Synthesis, characterization, and in vitro release10.1002/1097-4636(200111)57:2<313::AID-JBM1173>3.0.CO;2-E ↗
48. Chitosan sponges to locally deliver amikacin and vancomycin: a pilot in vitro evaluation10.1007/s11999-010-1324-6 ↗
49. Novel antibacterial nanofibrous PLLA scaffolds10.1016/j.jconrel.2010.05.035 ↗
50. Improvement of gentamicin poly(D, L-lactic-co-glycolic acid) microspheres for treatment of osteomyelitis induced by orthopedic procedures10.1016/j.biomaterials.2006.09.045 ↗
51. The controlled release of drugs from emulsified, sol gel processed silica microspheres10.1016/j.biomaterials.2008.09.066 ↗
52. Novel mesoporous silica-based antibiotic releasing scaffold for bone repair10.1016/j.actbio.2009.01.010 ↗
53. The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth
54. Infections from biomaterials and implants: a race for the surface
55. Antimicrobial tolerance and the significance of persister cells in recalcitrant chronic wound biofilms10.1111/j.1524-475X.2010.00651.x ↗
56. Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth-ethanedithiol with tobramycin in liposomes10.1093/jac/dkq036 ↗
57. Pharmacological inhibition of quorum sensing for the treatment of chronic bacterial infections10.1172/JCI20074 ↗
58. Aromatic D-amino acids act as chemoattractant factors for human leukocytes through a G protein-coupled receptor, GPR109B10.1073/pnas.0811844106 ↗
59. Characterization of the degradation mechanisms of lysine-derived aliphatic poly(ester urethane) scaffolds10.1016/j.biomaterials.2010.08.108 ↗
60. Local delivery of tobramycin from injectable biodegradable polyurethane scaffolds10.1163/156856209X410256 ↗
61. Improving bone formation in a rat femur segmental defect by controlling bone morphogenetic protein-2 release10.1089/ten.tea.2010.0446 ↗
62. Synthesis and characterization of an injectable allograft bone/polymer composite bone void filler with tunable mechanical properties10.1089/ten.tea.2009.0672 ↗
63. Injectable reactive biocomposites for bone healing in critical-size rabbit calvarial defects10.1088/1748-6041/7/2/024112 ↗
64. The effect of the local delivery of platelet-derived growth factor from reactive two-component polyurethane scaffolds on the healing in rat skin excisional wounds10.1016/j.biomaterials.2009.03.008 ↗
65. Sustained local delivery of siRNA from an injectable scaffold10.1016/j.biomaterials.2011.10.033 ↗
66. The solubility of amino acids and two glycine peptides in aqueous ethanol and dioxane solutions. Establishment of a hydrophobicity scale10.1016/S0021-9258(19)77210-X ↗
67. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary10.1093/cid/cir034 ↗
68. The use of a biodegradable, load-bearing scaffold as a carrier for antibiotics in an infected open fracture model10.1097/BOT.0b013e3181ed1349 ↗
69. The use of BMP-2 coupled - Nanosilver-PLGA composite grafts to induce bone repair in grossly infected segmental defects10.1016/j.biomaterials.2010.08.041 ↗
70. Dual delivery of an antibiotic and a growth factor addresses both the microbiological and biological challenges of contaminated bone fractures10.1517/17425247.2011.628655 ↗
71. Earlier debridement and antibiotic administration decrease infection